Last reviewed · How we verify
Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery
This study aims to examine the efficacy of levosimendan in terms of reducing postoperative mortality and severe morbidity in patients undergoing non-emergent surgery for coronary revascularisation with or without ischaemic mitral regurgitation and who may or may not require repair or replacement of the mitral valve and have a LVEF \< 35%.
Details
| Lead sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 2011-02 |
| Completion | 2014-11 |
Conditions
- Cardiac Surgery
Interventions
- Levosimendan
- Placebo
Primary outcomes
- Mortality — 30 days
Rate of mortality - Morbidity — 30 days
Rate of morbidity
Countries
Spain